GSK (LON:GSK) Given Buy Rating at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reissued their buy rating on shares of GSK (LON:GSK) in a research report released on Wednesday morning, Marketbeat reports. Deutsche Bank Aktiengesellschaft currently has a GBX 1,950 ($24.27) price target on the stock.

GSK has been the subject of a number of other research reports. Barclays restated an equal weight rating and issued a GBX 1,725 ($21.47) price target on shares of GSK in a research note on Monday, April 8th. Shore Capital restated a buy rating on shares of GSK in a research note on Thursday, March 7th. Finally, Berenberg Bank boosted their target price on shares of GSK from GBX 1,650 ($20.54) to GBX 1,820 ($22.66) and gave the company a buy rating in a research note on Wednesday, February 14th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of Hold and a consensus target price of GBX 1,630.63 ($20.30).

GSK Stock Down 0.1 %

Shares of LON:GSK opened at GBX 1,588.50 ($19.77) on Wednesday. The company has a current ratio of 0.88, a quick ratio of 0.73 and a debt-to-equity ratio of 140.82. The company has a fifty day simple moving average of GBX 1,663.74 and a 200 day simple moving average of GBX 1,545.06. The firm has a market cap of £64.97 billion, a PE ratio of 1,325.00, a price-to-earnings-growth ratio of 1.09 and a beta of 0.27. GSK has a 12-month low of GBX 1,302.60 ($16.22) and a 12-month high of GBX 1,719.80 ($21.41).

GSK Increases Dividend

The firm also recently announced a dividend, which was paid on Thursday, April 11th. Shareholders of record on Thursday, February 22nd were paid a dividend of GBX 16 ($0.20) per share. This is a positive change from GSK’s previous dividend of $14.00. The ex-dividend date was Thursday, February 22nd. This represents a yield of 1.04%. GSK’s payout ratio is presently 5,333.33%.

Insider Buying and Selling at GSK

In other news, insider Urs Rohner purchased 434 shares of GSK stock in a transaction dated Wednesday, March 20th. The stock was bought at an average price of GBX 1,662 ($20.69) per share, with a total value of £7,213.08 ($8,979.31). In other news, insider Urs Rohner purchased 434 shares of GSK stock in a transaction dated Wednesday, March 20th. The stock was bought at an average price of GBX 1,662 ($20.69) per share, with a total value of £7,213.08 ($8,979.31). Also, insider Emma Walmsley sold 139,792 shares of the business’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of GBX 1,658 ($20.64), for a total transaction of £2,317,751.36 ($2,885,287.39). Insiders acquired a total of 19,802 shares of company stock worth $31,381,484 over the last 90 days. Insiders own 1.71% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.